123 related articles for article (PubMed ID: 15606435)
1. Lornoxicam pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Zhang Y; Zhong D; Si D; Guo Y; Chen X; Zhou H
Br J Clin Pharmacol; 2005 Jan; 59(1):14-7. PubMed ID: 15606435
[TBL] [Abstract][Full Text] [Related]
2. [Impact of cytochrome P450 CYP2C9 variant allele CYP2C9 * 3 on the pharmacokinetics of glibenclamide and lornoxicam in Chinese subjects].
Zhang YF; Chen XY; Guo YJ; Si DY; Zhou H; Zhong DF
Yao Xue Xue Bao; 2005 Sep; 40(9):796-9. PubMed ID: 16342679
[TBL] [Abstract][Full Text] [Related]
3. Effect of the CYP2C9*3 allele on lornoxicam metabolism.
Liu YL; Zhang W; Tan ZR; Ouyang DS; Luo CH; Liu ZQ; Qiu Y; Chen Y; He YJ; Zhou G; Zhou HH
Clin Chim Acta; 2006 Feb; 364(1-2):287-91. PubMed ID: 16182270
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians.
Vianna-Jorge R; Perini JA; Rondinelli E; Suarez-Kurtz G
Clin Pharmacol Ther; 2004 Jul; 76(1):18-26. PubMed ID: 15229460
[TBL] [Abstract][Full Text] [Related]
5. Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans.
Guo Y; Zhang Y; Wang Y; Chen X; Si D; Zhong D; Fawcett JP; Zhou H
Drug Metab Dispos; 2005 Jun; 33(6):749-53. PubMed ID: 15764711
[TBL] [Abstract][Full Text] [Related]
6. Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.
Perini JA; Vianna-Jorge R; Brogliato AR; Suarez-Kurtz G
Clin Pharmacol Ther; 2005 Oct; 78(4):362-9. PubMed ID: 16198655
[TBL] [Abstract][Full Text] [Related]
7. Effects of the CYP2C9*1/*13 genotype on the pharmacokinetics of lornoxicam.
Choi CI; Kim MJ; Jang CG; Park YS; Bae JW; Lee SY
Basic Clin Pharmacol Toxicol; 2011 Dec; 109(6):476-80. PubMed ID: 21726410
[TBL] [Abstract][Full Text] [Related]
8. Effect of CYP2C9*3 allele on the pharmacokinetics of naproxen in Korean subjects.
Bae JW; Kim JH; Choi CI; Kim MJ; Kim HJ; Byun SA; Chang YS; Jang CG; Park YS; Lee SY
Arch Pharm Res; 2009 Feb; 32(2):269-73. PubMed ID: 19280158
[TBL] [Abstract][Full Text] [Related]
9. Catalytic roles of CYP2C9 and its variants (CYP2C9*2 and CYP2C9*3) in lornoxicam 5'-hydroxylation.
Iida I; Miyata A; Arai M; Hirota M; Akimoto M; Higuchi S; Kobayashi K; Chiba K
Drug Metab Dispos; 2004 Jan; 32(1):7-9. PubMed ID: 14709614
[TBL] [Abstract][Full Text] [Related]
10. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms.
García-Martín E; Martínez C; Tabarés B; Frías J; Agúndez JA
Clin Pharmacol Ther; 2004 Aug; 76(2):119-27. PubMed ID: 15289789
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.
Lee CR; Pieper JA; Hinderliter AL; Blaisdell JA; Goldstein JA
Clin Pharmacol Ther; 2002 Nov; 72(5):562-71. PubMed ID: 12426520
[TBL] [Abstract][Full Text] [Related]
12. Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J; Brockmöller J
Clin Pharmacol Ther; 2005 Jan; 77(1):1-16. PubMed ID: 15637526
[TBL] [Abstract][Full Text] [Related]
13. Acenocoumarol pharmacokinetics in relation to cytochrome P450 2C9 genotype.
Thijssen HH; Ritzen B
Clin Pharmacol Ther; 2003 Jul; 74(1):61-8. PubMed ID: 12844136
[TBL] [Abstract][Full Text] [Related]
14. [Determination of lornoxicam in human plasma by LC/MS/MS].
Zeng YL; Chen XY; Zhang YF; Zhong DF
Yao Xue Xue Bao; 2004 Feb; 39(2):132-5. PubMed ID: 15127622
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 polymorphism in non-steroidal anti-inflammatory drugs-induced gastropathy.
Ma J; Yang XY; Qiao L; Liang LQ; Chen MH
J Dig Dis; 2008 May; 9(2):79-83. PubMed ID: 18419640
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
17. [Influence of cytochrom P450 CYP2C9 polymorphism on the pharmacokinetics of tolbutamide metabolism using oligonucleotide genotyping microarray].
Li J; Wen SY; Wang R; Chen K; Fang Y; Pei F; Wang SQ
Yao Xue Xue Bao; 2005 Aug; 40(8):695-9. PubMed ID: 16268502
[TBL] [Abstract][Full Text] [Related]
18. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.
Martínez C; García-Martín E; Blanco G; Gamito FJ; Ladero JM; Agúndez JA
Br J Clin Pharmacol; 2005 Jan; 59(1):62-9. PubMed ID: 15606441
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic relevance of the CYP2C9*3 allele in a tenoxicam bioequivalence study performed on Spaniards.
Peiró AM; Novalbos J; Zapater P; Moreu R; López-Rodríguez R; Rodríguez V; Abad-Santos F; Horga JF
Pharmacol Res; 2009 Jan; 59(1):62-8. PubMed ID: 18992346
[TBL] [Abstract][Full Text] [Related]
20. Role of human liver microsomal CYP2C9 in the biotransformation of lornoxicam.
Bonnabry P; Leemann T; Dayer P
Eur J Clin Pharmacol; 1996; 49(4):305-8. PubMed ID: 8857077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
